| Literature DB >> 29434734 |
Yanhong Meng1, Ling Zong2, Ziteng Zhang2, Youdong Han1, Yanhui Wang3.
Abstract
We aimed to evaluate the changes in left ventricular structure and function in hypertensive patients with coronary artery disease before and after percutaneous coronary intervention (PCI) using real-time three-dimensional echocardiography. Two hundred and eighty hypertensive patients with coronary artery disease undergoing PCI and 120 cases who did not receive PCI in our hospital were selected as the subjects of our study. All patients were administered with routine antiplatelet, anticoagulant, lipid-lowering, antihypertensive, dilating coronary artery and other medications. The left ventricular systolic function and systolic synchrony index changes before and after subjects were treated by PCI were analyzed using three-dimensional echocardiography. At 2 days before surgery, there were no significant differences in the left ventricular end-diastolic volume, left ventricular end-systolic volume (LVESV) and ejection fraction (EF) between the two patient groups (P>0.05). At 3 months and 9 months, the two key time points after PCI, the LVESV level in the PCI group was distinctly decreased, while EF was significantly increased (P<0.05). In addition, before treatment, there were no significant differences in the parameters of time from the corresponding segment of the myocardium to the minimal systolic volume in two patient groups, such as Tmsv-16SD, Tmsv-16Dif, Tmsv-12SD, Tmsv-12Dif, Tmsv-6SD and Tmsv-6Dif (P>0.05); however, the parameters of time from the corresponding segment of the myocardium to the minimal systolic volume in patients in the PCI group were significantly reduced at 3 and 9 months after surgery (P<0.05). Three-dimensional echocardiography can evaluate the critical parameters in the prognosis of hypertensive patients with coronary artery disease after PCI accurately and in real-time, which may play a significant role.Entities:
Keywords: PCI; essential hypertension; left ventricular systolic function; left ventricular systolic synchrony; percutaneous coronary intervention; three-dimensional echocardiography
Year: 2017 PMID: 29434734 PMCID: PMC5774471 DOI: 10.3892/etm.2017.5544
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparisons of general data of the hypertensive patients.
| Parameters | PCI group | Control group | P-value |
|---|---|---|---|
| Mean age (years) | 62.47±3.82 | 64.04±4.19 | 0.842 |
| Male, n (%) | 193 (68.9) | 84 (70.0) | 0.747 |
| Smoking, n (%) | 104 (37.1) | 40 (33.3) | 0.673 |
| Fasting blood-glucose (mmol/l) | 5.43±0.43 | 5.51±0.35 | 0.913 |
| Diabetes, n (%) | 79 (28.2) | 32 (26.7) | 0.583 |
| Serum creatinine (µmol/l) | 92.1±9.1 | 93.1±11.8 | 0.738 |
| Homocysteine (µmol/l) | 13.8±2.4 | 13.9±1.7 | 0.545 |
| hs-CRP (mg/l) | 0.89±0.17 | 0.91±0.21 | 0.701 |
| Aspirin, n (%) | 280 (100.0) | 120 (100.0) | 0.662 |
| Clopidogrel, n (%) | 242 (86.4) | 105 (87.5) | 0.843 |
| Ticagrelor, n (%) | 38 (13.6) | 15 (12.5) | 0.274 |
| Statins, n (%) | 276 (98.6) | 114 (95.0) | 0.837 |
| ACEI/ARB, n (%) | 185 (66.1) | 81 (67.5) | 0.583 |
| β-blocker, n (%) | 219 (78.2) | 93 (77.5) | 0.669 |
| Calcium antagonist, n (%) | 86 (30.7) | 38 (31.7) | 0.343 |
| Nitrates, n (%) | 251 (89.6) | 109 (90.8) | 0.554 |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist.
Figure 1.Real-time three-dimensional echocardiography and two-dimensional echocardiography. Left, real-time three-dimensional echocardiography; right, two-dimensional echocardiography.
Changes in left ventricular volume, ejection and systolic function at different time points in patients receiving PCI.
| Parameters | Test time | Control group (n=120) | PCI group (n=280) | P-value |
|---|---|---|---|---|
| LVEDV (ml) | 2 days before treatment | 92.41±8.74 | 92.08±7.09 | 0.311 |
| 3 months after treatment | 92.05±8.32 | 92.54±5.91 | 0.284 | |
| 9 months after treatment | 92.05±6.71 | 92.07±8.22 | 0.536 | |
| LVESV (ml) | 2 days before treatment | 49.28±4.92 | 48.93±5.01 | 0.723 |
| 3 months after treatment | 53.06±7.04 | 47.83±6.61 | 0.015 | |
| 9 months after treatment | 49.33±4.29 | 44.11±9.72 | 0.013 | |
| LVEF (%) | 2 days before treatment | 46.05±3.21 | 46.04±3.92 | 0.542 |
| 3 months after treatment | 45.94±3.19 | 49.25±3.86 | 0.006 | |
| 9 months after treatment | 46.38±4.33 | 51.74±3.22 | 0.011 |
Changes in left ventricular systolic volume and systolic function at different time points in hypertensive patients with coronary artery disease receiving PCI.
| Parameters | Test time | Control group (n=120) | PCI group (n=280) | P-value |
|---|---|---|---|---|
| Tmsv-16SD | 2 days before treatment | 49.25±14.28 | 40.19±11.93 | 0.662 |
| Tmsv-12SD | 43.66±5.91 | 44.33±7.06 | 0.187 | |
| Tmsv-6SD | 43.27±8.45 | 43.18±7.32 | 0.243 | |
| Tmsv-16Dif | 79.15±11.31 | 80.18±12.07 | 0.228 | |
| Tmsv-12Dif | 70.43±10.03 | 69.18±9.06 | 0.184 | |
| Tmsv-6 Dif | 59.45±8.25 | 59.02±9.51 | 0.394 | |
| Tmsv-16SD | 3 months after treatment | 53.73±11.02 | 46.06±9.83 | 0.011 |
| Tmsv-12SD | 39.21±4.22 | 21.36±3.11 | 0.021 | |
| Tmsv-6SD | 39.42±2.19 | 19.04±2.33 | 0.033 | |
| Tmsv-16Dif | 80.16±9.42 | 49.33±15.15 | 0.018 | |
| Tmsv-12Dif | 70.62±7.14 | 50.16±2.94 | 0.019 | |
| Tmsv-6 Dif | 63.42±7.01 | 51.22±4.05 | 0.003 | |
| Tmsv-16SD | 9 months after treatment | 49.99±3.84 | 19.55±3.21 | 0.014 |
| Tmsv-12SD | 39.88±3.52 | 20.71±3.83 | 0.031 | |
| Tmsv-6SD | 39.07±5.83 | 20.21±3.14 | 0.008 | |
| Tmsv-16Dif | 69.21±4.05 | 51.22±5.05 | 0.015 | |
| Tmsv-12Dif | 59.03±11.52 | 41.37±8.21 | 0.018 | |
| Tmsv-6 Dif | 60.41±9.04 | 41.62±5.64 | 0.009 |
Comparisons of other function parameters of left ventricular in subjects (mean ± SD).
| Group | No. of cases | GLS (%) | GLSRs (1/sec) | EF (%) |
|---|---|---|---|---|
| PCI group | 280 | −19.06±1.37[ | 1.05±0.29[ | 65.33±6.25 |
| Control group | 120 | −22.33±2.15 | 1.25±0.31 | 67.03±5.75 |
P<0.05, compared with the control group.
Comparisons routine heart structure parameters of left ventricular in subjects (mean ± SD).
| Group | No. of cases | LVEDD (cm) | IVSD (cm) | LVPWD (cm) | LVMI (g/m2) |
|---|---|---|---|---|---|
| PCI group | 280 | 4.86±0.37[ | 1.04±0.29[ | 0.94±0.26[ | 65.33±6.25[ |
| Control group | 120 | 4.33±0.15 | 0.88±0.31 | 0.78±0.33 | 67.03±5.75 |
P<0.05, compared with the control group.
Comparisons of clinical biochemical parameters in subjects (mean ± SD).
| Group | No. of cases | Systolic blood pressure (mmHg) | Diastolic blood pressure (mmHg) | Hemoglobin (g/dl) | Hematocrit (%) |
|---|---|---|---|---|---|
| PCI group | 280 | 133.6±10.7[ | 76.4±9.2 | 11.94±2.6[ | 35.8±4.5 |
| Control group | 120 | 124.3±9.5 | 75.8±9.3 | 10.78±3.1 | 36.3±5.7 |
P<0.05, compared with the control group.